Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent
Nicholas F. Dybdal‐Hargreaves, April L. Risinger, Susan L. Mooberry
Clinical Cancer Research (2015) Vol. 21, Iss. 11, pp. 2445-2452
Open Access | Times Cited: 199

Showing 1-25 of 199 citing articles:

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant P. Chawla, Robert G. Maki, et al.
The Lancet (2016) Vol. 387, Iss. 10028, pp. 1629-1637
Open Access | Times Cited: 706
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Darcy Bates, Alan Eastman
British Journal of Clinical Pharmacology (2016) Vol. 83, Iss. 2, pp. 255-268
Open Access | Times Cited: 275
New opportunities and challenges of natural products research: When target identification meets single-cell multiomics
Yuyu Zhu, Zijun Ouyang, Haojie Du, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 11, pp. 4011-4039
Open Access | Times Cited: 247
A Bayesian machine learning approach for drug target identification using diverse data types
Neel S. Madhukar, Prashant K. Khade, Linda Huang, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 211
Antibody–drug conjugates: Recent advances in payloads
Zhijia Wang, Hanxuan Li, Lantu Gou, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 10, pp. 4025-4059
Open Access | Times Cited: 102
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
George D. Demetri, Patrick Schöffski, Giovanni Grignani, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 30, pp. 3433-3439
Closed Access | Times Cited: 151
Marine Sponge Natural Products with Anticancer Potential: An Updated Review
Cinzia Calcabrini, Elena Catanzaro, Anupam Bishayee, et al.
Marine Drugs (2017) Vol. 15, Iss. 10, pp. 310-310
Open Access | Times Cited: 134
Synthesis and anticancer activity of novel water soluble benzimidazole carbamates
Jae Eun Cheong, Michela Zaffagni, Ivy Chung, et al.
European Journal of Medicinal Chemistry (2017) Vol. 144, pp. 372-385
Closed Access | Times Cited: 103
Advances in sarcoma diagnostics and treatment
Amanda R. Dancsok, Karama Asleh, Torsten O. Nielsen
Oncotarget (2016) Vol. 8, Iss. 4, pp. 7068-7093
Open Access | Times Cited: 99
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 11, pp. 3061-3068
Open Access | Times Cited: 99
In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
Shigeto Ueda, Toshiaki Saeki, Hideki Takeuchi, et al.
British Journal of Cancer (2016) Vol. 114, Iss. 11, pp. 1212-1218
Open Access | Times Cited: 98
Advances in exploring the therapeutic potential of marine natural products
Xiao Liang, Danmeng Luo, Hendrik Luesch
Pharmacological Research (2019) Vol. 147, pp. 104373-104373
Open Access | Times Cited: 95
Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy
Stephanie M. Myers, Ian Collins
Future Medicinal Chemistry (2016) Vol. 8, Iss. 4, pp. 463-489
Open Access | Times Cited: 92
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas
Alessandro De Vita, Laura Mercatali, Federica Recine, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 6233-6246
Open Access | Times Cited: 88
Microtubule-Targeting Drugs: More than Antimitotics
Roma Kaul, April L. Risinger, Susan L. Mooberry
Journal of Natural Products (2019) Vol. 82, Iss. 3, pp. 680-685
Closed Access | Times Cited: 84
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 14, pp. 3905-3915
Open Access | Times Cited: 77
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
Matthieu Roulleaux Dugage, Elise F. Nassif, Antoîne Italiano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
A review of FDA approved drugs and their formulations for the treatment of breast cancer
Mohini Chaurasia, Romi Singh, Srija Sur, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 23
Developing natural product drugs: Supply problems and how they have been overcome
David Newman
Pharmacology & Therapeutics (2015) Vol. 162, pp. 1-9
Closed Access | Times Cited: 74
Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, et al.
Anticancer Research (2018) Vol. 38, Iss. 5
Open Access | Times Cited: 72
Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new
Anna Maria Frezza, Silvia Stacchiotti, Alessandro Gronchi
BMC Medicine (2017) Vol. 15, Iss. 1
Open Access | Times Cited: 68
Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts
Masamichi Takahashi, Shunichiro Miki, Kenji Fujimoto, et al.
Cancer Science (2019) Vol. 110, Iss. 7, pp. 2247-2257
Open Access | Times Cited: 59
Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment
Badrul Islam, Maryam B. Lustberg, Nathan P. Staff, et al.
Journal of the Peripheral Nervous System (2019) Vol. 24, Iss. S2
Closed Access | Times Cited: 59
Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
Dia Advani, Sudhanshu Sharma, Smita Kumari, et al.
Anti-Cancer Agents in Medicinal Chemistry (2021) Vol. 22, Iss. 3, pp. 433-468
Closed Access | Times Cited: 48
Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma†
Akira Kawai, Nobuhito Araki, Yoichi Naito, et al.
Japanese Journal of Clinical Oncology (2016) Vol. 47, Iss. 2, pp. 137-144
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top